Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs
William H. Ludlam
Dr. Ludlam, a highly-regarded academic leader in the pituitary and rare disease space, comes to Chiasma after spending the last four years at
, where he served most recently as Senior Medical Director for the
U.S. Clinical Development
and Medical Affairs (USCDMA), Pituitary Disorders, Rare Diseases Franchise.
is currently a leading seller of injectable octreotide, one of the standard treatment options for patients suffering from acromegaly.
role at Chiasma
, Dr. Ludlam
will be responsible for developing strategy around clinical and technical information to support the planned commercial launch of Mycapssa™
for the maintenance treatment of adults with acromegaly.
will also lead all medical review activities around the Company's product education campaign, including its presence at key scientific events.
"Dr. Ludlam's extensive academic and industry experience in the rare disease space, particularly pituitary disorders, makes him an ideal choice to help lead the medical strategy for our anticipated launch of Mycapssa™ in 2016," said
has worked firsthand with acromegaly patients, both in his
current role at
in 2012, Dr. Ludlam spent 15 years in a number of academic and clinical roles.
From 2007 to 2011, he served as medical director at the Seattle Pituitary Center within the
Swedish Medical Center
, and from 2002 to 2006 as medical director of the Pituitary Unit at the
Oregon Health and Science University
. Dr. Ludlam
helped develop both treatment centers and conducted clinical research for novel treatment options for pituitary disorders while actively treating patients with acromegaly and Cushing's disease, among other conditions.
Dr. Ludlam holds an M.D. and Ph.D. from the
"I am extremely pleased to be joining Chiasma
prior to the potential launch of Mycapssa™
," said Dr. Ludlam